From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study
Baseline | End of study | P* | |
---|---|---|---|
Hemoglobin (g/dL) | 10.2 ± 1.3 | 10.1 ± 0.8 | 0.75 |
Hematocrit (%) | 31.7 ± 3.9 | 31.2 ± 2.5 | 0.66 |
Platelet count (× 104 cells/mm3) | 16.2 ± 5.7 | 16.1 ± 5.3 | 0.86 |
Blood urea nitrogen (mg/dL) | 57.0 ± 13.3 | 60.7 ± 11.8 | 0.31 |
Serum creatinine (mg/dL) | 9.6 ± 2.2 | 10.0 ± 2.5 | 0.55 |
Serum sodium (mEq/L) | 137.7 ± 2.2 | 137.0 ± 2.4 | 0.09 |
Serum potassium (mEq/L) | 4.8 ± 0.6 | 5.2 ± 0.9 | 0.08 |
Serum chloride (mEq/L) | 107.1 ± 2.4 | 107.0 ± 2.0 | 0.93 |
Serum calcium (mEq/L) | 8.8 ± 0.6 | 8.8 ± 0.7 | 0.84 |
Serum inorganic phosphorus (mEq/L) | 5.2 ± 1.1 | 5.2 ± 1.5 | 0.99 |
Aspartate transaminase (U/L) | 11.8 ± 4.1 | 9.4 ± 3.0 | 0.03 |
Alanine aminotransferase (U/L) | 8.6 ± 2.8 | 6.7 ± 2.6 | < 0.01 |
Alkaline phosphatase (U/L) | 278.8 ± 102.1 | 265.2 ± 111.6 | 0.34 |
Lactate dehydrogenase (U/L) | 176.1 ± 24.1 | 170.6 ± 35.4 | 0.41 |
Total protein (g/dL) | 6.2 ± 0.5 | 6.2 ± 0.6 | 0.95 |
Intact PTH (pg/mL) | 284.8 ± 224.4 | 306.1 ± 355.1 | 0.71 |